Physician profile
George Weidig
NPI 1730180464
$680.17
in general payments reported to CMS, 2019-2025
17 companies · $17.42 in 2025
The $17.42 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $124 · 2021: $148 · 2023: $82.74 · 2024: $133 · 2025: $17.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $233.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $128.66 | 2019-2024 | Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $92.27 | 2019-2024 | Eliquis, Camzyos |
| Abbvie INC. | $80.51 | 2021-2024 | |
| Pfizer INC. | $61.36 | 2020-2023 | |
| Abbott Laboratories | $61.01 | 2021-2023 | Freestyle Libre 3 |
| Amgen INC. | $41.68 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.07 | 2020-2024 | Xifaxan |
| Allergan, INC. | $28.19 | 2020 | |
| Amarin Pharma, INC. | $25.21 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $23.54 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $17.83 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.42 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $16.35 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.05 | 2020 | |
| Depuy Synthes Sales INC. | $13.08 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $12.69 | 2023 | Wavewriter Alpha Prime 16 |
| Teva Pharmaceuticals USA, INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Weidig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.